Top Markets
#1 Cortex Cortex +32.85%
#2 EXOD EXOD +9.04%
#3 Solstice Solstice +7.20%
#4 MarsCoin MarsCoin +7.14%
#5 peaq peaq +5.99%
#6 Official Trump Official Trump +5.88%
#7 DexNet DexNet +5.76%
#8 Versatize Coin Versatize Coin +5.26%
#9 aelf aelf +4.66%
#10 Utya Utya +4.66%
Coin of the day
Cortex Cortex
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Onesource Specialty Pharma Ltd. Onesource Specialty Pharma Ltd.

Onesource Specialty Pharma Ltd.

ONESOURCE
Rangering i aksjer #6664
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on... OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Aksjekurs
$16.75
Sist synkronisert: 2026-08-27
Markedsverdi
$1.92B
Endring (1 dag)
2.28%
Endring (1 år)
-20.92%
Land
IN
Handel Onesource Specialty Pharma Ltd. (ONESOURCE)

Kategori

Healthcare
P/E-forhold for Onesource Specialty Pharma Ltd. (ONESOURCE)
P/E-forhold per 2026 TTM: 0
Ifølge Onesource Specialty Pharma Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Onesource Specialty Pharma Ltd. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.